IL17A and psoriasis: Considering the potential influence of body mass index (BMI) on the quantitative results of LCFAs in serum samples among psoriasis patients, although healthy volunteers and psoriasis patients had similar BMIs, a significant increase in BMI was observed after anti-IL-17A mAb treatment.